title: Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy.
abstract: Asparaginase is an expensive drug, but important in childhood acute lymphoblastic leukemia. In order to compare costs of PEGasparaginase, Erwinia asparaginase and native E. coli asparaginase, we performed a cost-analysis in the Dutch Childhood Oncology Group ALL-10 medium-risk group intensification protocol. Treatment costs were calculated based on patient level data of 84 subjects, and were related to the occurrence of allergy to PEGasparaginase. Simultaneously, decision tree and sensitivity analyses were conducted. The total costs of the intensification course of 30 weeks were $57,893 in patients without PEGasparaginase allergy (n=64). The costs were significantly higher ($113,558) in case of allergy (n=20) necessitating a switch to Erwinia asparaginase. Simulated scenarios (decision tree analysis) using native E. coli asparaginase in intensification showed that the costs of PEGasparaginase were equal to those of native E. coli asparaginase. Also after sensitivity analyses, the costs for PEGasparaginase were equal to those of native E. coli asparaginase. Intensification treatment with native E. coli asparaginase, followed by a switch to PEGasparaginase, and subsequently to Erwinia asparaginase in case of allergy had similar overall costs compared to the treatment with PEGasparaginase as the first-line drug (followed by Erwinia asparaginase in the case of allergy). PEGasparaginase is preferred over native E. coli asparaginase, because it is administered less frequently, with less day care visits. PEGasparaginase is less immunogenic than native E. coli asparaginase and is not more expensive. Asparaginase costs are mainly determined by the percentage of patients who are allergic and require a switch to Erwinia asparaginase.
authors: Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children’s Hospital, Rotterdam, The Netherlands.
authors: Wing H
authors: WH
authors: Tong
authors: Inge M
authors: IM
authors: van der Sluis
authors: Cathelijne J M
authors: CJ
authors: Alleman
authors: Raphaële R L
authors: RR
authors: van Litsenburg
authors: Gertjan J L
authors: GJ
authors: Kaspers
authors: Rob
authors: R
authors: Pieters
authors: Carin A
authors: CA
authors: Uyl-de Groot
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D001215:Asparaginase / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003198:Computer Simulation; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D005260:Female; D017048:Health Care Costs; D006801:Humans; D007223:Infant; D008297:Male; D018803:Models, Economic; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000191:economics*
chemical_list: D000970:Antineoplastic Agents; D001215:Asparaginase
references: Pediatr Blood Cancer. 2011 Dec 1;57(6):1005-10
references: 21618420
references: Pediatr Blood Cancer. 2012 May;58(5):701-7
references: 21793184
references: Formulary. 1995 Jul;30(7):388-93
references: 10151730
references: Cancer. 2011 Jan 15;117(2):238-49
references: 20824725
references: Leukemia. 1999 Mar;13(3):335-42
references: 10086723
references: J Clin Oncol. 1997 Jun;15(6):2222-30
references: 9196134
references: Exp Cell Res. 1995 Oct;220(2):283-91
references: 7556435
references: Blood. 2002 Apr 15;99(8):2734-9
references: 11929760
references: Expert Opin Pharmacother. 2007 Aug;8(12):1977-84
references: 17696798
references: Blood. 2002 Mar 15;99(6):1986-94
references: 11877270
references: J Pediatr Hematol Oncol. 2002 Mar-Apr;24(3):175-81
references: 11990302
references: Blood. 2001 Mar 1;97(5):1211-8
references: 11222362
references: Blood. 2007 Feb 1;109(3):896-904
references: 17003366
references: Pediatr Blood Cancer. 2011 Sep;57(3):378-84
references: 21337682
references: Blood. 2008 Dec 15;112(13):4832-8
references: 18805963
references: Blood. 2010 Feb 18;115(7):1351-3
references: 20007809
references: Blood. 2011 Nov 24;118(22):5774-82
references: 21940824
references: Br J Haematol. 2010 May;149(3):410-3
references: 20201945
references: J Clin Oncol. 2001 Mar 1;19(5):1297-303
references: 11230471
references: Jpn J Cancer Res. 1986 Dec;77(12):1264-70
references: 3102431
references: Cancer Treat Rep. 1979 Jun;63(6):1127-32
references: 466651
references: N Engl J Med. 2012 Apr 12;366(15):1371-81
references: 22494120
references: J Clin Oncol. 2005 Oct 1;23(28):7161-7
references: 16192600